Is $5.5 billion justice—or just closure without accountability? In this powerful and deeply personal reflection, Rob Kent, Esq., President of Kent Strategic Advisors and former New York State drug policy official, examines the conclusion of the federal criminal case against Purdue Pharma. For policymakers, clinicians, and those impacted by the opioid crisis, Kent’s message is clear: financial penalties alone are not enough.

What if addiction treatment didn’t start with abstinence? Dr. Andrew Tatarsky presents a model that meets people where they are, focusing on engagement, collaboration, and gradual change. This approach increases retention and creates real-world progress.

Psychedelic therapy is gaining momentum in modern mental health care—but the story isn’t simple. Joshua Bennett-Johnson, LADC-II, licensed counselor, explores both the promise and the complexity of this emerging field. Substances once dismissed are now being fast-tracked for conditions like depression, PTSD, and addiction.